87 related articles for article (PubMed ID: 22136721)
1. Successful use of acarbose to manage post-prandial glycaemia in two patients with type 1 diabetes on continuous subcutaneous insulin infusion.
Dash S; Crisp S; Hartnell S; Donald S; Davenport K; Simmons D; Evans M
Diabetes Res Clin Pract; 2012 Mar; 95(3):e49-51. PubMed ID: 22136721
[TBL] [Abstract][Full Text] [Related]
2. The dual-wave bolus feature in continuous subcutaneous insulin infusion pumps controls prolonged post-prandial hyperglycaemia better than standard bolus in Type 1 diabetes.
Lee SW; Cao M; Sajid S; Hayes M; Choi L; Rother C; de León R
Diabetes Nutr Metab; 2004 Aug; 17(4):211-6. PubMed ID: 15575341
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
4. Influence of acarbose on post-prandial insulin requirements in patients with Type 1 diabetes.
Juntti-Berggren L; Pigon J; Hellström P; Holst JJ; Efendic S
Diabetes Nutr Metab; 2000 Feb; 13(1):7-12. PubMed ID: 10824717
[TBL] [Abstract][Full Text] [Related]
5. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
6. Benefits of a bolus calculator in pre- and postprandial glycaemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII).
Shashaj B; Busetto E; Sulli N
Diabet Med; 2008 Sep; 25(9):1036-42. PubMed ID: 18937673
[TBL] [Abstract][Full Text] [Related]
7. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
[TBL] [Abstract][Full Text] [Related]
8. Use of acarbose for eliminating the interval between meal consumption and insulin injection in patients with Type 1 diabetes.
Koch HH; Wudy A; Eberlein G; Quast C
Diabetes Nutr Metab; 1999 Jun; 12(3):195-201. PubMed ID: 10554902
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
Sieradzki J; Soszyński P
Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
[TBL] [Abstract][Full Text] [Related]
10. Improving post-prandial control with Humalog and Humalog mixtures.
Lüddeke HJ
Int J Clin Pract Suppl; 2000 Sep; (112):23-8. PubMed ID: 11064948
[No Abstract] [Full Text] [Related]
11. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
[TBL] [Abstract][Full Text] [Related]
12. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
[TBL] [Abstract][Full Text] [Related]
13. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus.
Dimitriadis G; Karaiskos C; Raptis S
Horm Metab Res; 1986 Apr; 18(4):253-5. PubMed ID: 3519413
[TBL] [Abstract][Full Text] [Related]
14. Many patients with Type 1 diabetes estimate their prandial insulin need inappropriately.
Ahola AJ; Mäkimattila S; Saraheimo M; Mikkilä V; Forsblom C; Freese R; Groop PH;
J Diabetes; 2010 Sep; 2(3):194-202. PubMed ID: 20923484
[TBL] [Abstract][Full Text] [Related]
15. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
Ledermann H; Höxter G
Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
[TBL] [Abstract][Full Text] [Related]
16. [Consensus document on continuous subcutaneous insulin infusion (CSII) treatment in paediatrics with type I diabetes].
Barrio Castellanos R; García Cuartero B; Gómez Gila A; González Casado I; Hermoso López F; Luzuriaga Tomás C; Oyarzabal Irigoyen M; Rica Etxebarria I; Rodríguez Rigual M; Torres Lacruz M;
An Pediatr (Barc); 2010 May; 72(5):352.e1-4. PubMed ID: 20409767
[TBL] [Abstract][Full Text] [Related]
17. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
Hermanns N; Burkert A; Haak T
Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):310-4. PubMed ID: 15216448
[TBL] [Abstract][Full Text] [Related]
18. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
Laakso M
Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
[No Abstract] [Full Text] [Related]
19. Post-prandial hyperglycaemia and prevention of cardiovascular disease.
Davies MJ
Diabet Med; 2005 Jan; 22 Suppl 1():6-9. PubMed ID: 15610148
[No Abstract] [Full Text] [Related]
20. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
